We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 6,492

Paying Royalties for Technology that Competitors Can Use for Free - AG Wathelet’s Genentech Opinion
  • McDermott Will & Emery
  • European Union
  • April 28 2016

The Court of Justice of the European Union (CJEU) recently issued its opinion on a question referred to it by the Paris Court of Appeal regarding the


MSD’s ‘surprising’ patent battle could continue
  • Davies Collison Cave
  • USA
  • April 28 2016

Originally published in Pharma in Focus MSD's tactics in a patent opposition case against Genentech involving an unnamed interleukin-17 inhibitor have


Future Infringement Supports Speculative Jurisdiction
  • McDermott Will & Emery
  • USA
  • April 28 2016

Addressing personal jurisdiction in suits under 35 USC 271(e)(2), the US Court of Appeals for the Federal Circuit held that a state in which an


The Federal Court of Appeal determines the incorrect date to assess obviousness-type double patenting, but leaves the determination of the correct date for another day
  • Borden Ladner Gervais LLP
  • Canada
  • April 28 2016

The Federal Court of Appeal has upheld an earlier decision (2015 FC 17) prohibiting Mylan from obtaining its Notice of Compliance until after the


Biotech Industry Supports Cert in Sequenom to Avert “Crisis of Patent Law and Medical Innovation”
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • April 27 2016

The biotechnology and life sciences community has voiced broad support for Sequenom’s recent request that the Supreme Court review the Federal


PTO toughens its stance against ANVISA patent activity
  • Daniel Advogados
  • Brazil
  • April 27 2016

In 1999 the Brazilian Industrial Propriety Law was amended to include Article 229-C, which requires the National Health Surveillance Agency (ANVISA


Eli Lilly’s Cialis patent withstands double patenting and utility challenges on appeal
  • Gowling WLG
  • Canada
  • April 26 2016

The Federal Court of Appeal has provided guidance on the law of obviousness-type double patenting in dismissing Mylan’s appeal pertaining to Eli


Federal Circuit Strikes Another Blow Against Patentable Subject Matter in Biotechnology
  • Fredrikson & Byron PA
  • USA
  • April 26 2016

In Genetic Technologies Ltd. v. Merial LLC, the Court of Appeals for the Federal Circuit recently issued an opinion holding yet another biotech


3 Reasons Why Supreme Court Should Grant Cert in Critical Biotech Case
  • Arent Fox LLP
  • USA
  • April 26 2016

In Ariosa Diagnostics, Inc. v. Sequenom, Inc., the Federal Circuit, relying on Mayo Collaborative Servs. V. Prometheus Labs., Inc., held that


Will The Celsis Appeal Put An End To 101 Rejections Of Laboratory Method Claims?
  • Foley & Lardner LLP
  • USA
  • April 26 2016

On April 5, 2016, the Federal Circuit heard oral arguments in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., where the U.S. District Court for the